Symmetry Peak Management LLC acquired a new position in PolyPid Ltd. (NASDAQ:PYPD – Free Report) in the second quarter, HoldingsChannel.com reports. The institutional investor acquired 100,881 shares of the company’s stock, valued at approximately $512,000.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. BNP Paribas Financial Markets increased its stake in shares of PolyPid by 56.1% during the third quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock valued at $32,000 after purchasing an additional 3,500 shares in the last quarter. AIGH Capital Management LLC boosted its position in shares of PolyPid by 26.1% in the 4th quarter. AIGH Capital Management LLC now owns 1,342,972 shares of the company’s stock worth $5,828,000 after purchasing an additional 277,844 shares in the last quarter. HighTower Advisors LLC purchased a new stake in shares of PolyPid in the 4th quarter worth approximately $44,000. Jane Street Group LLC purchased a new stake in shares of PolyPid in the 4th quarter worth approximately $66,000. Finally, ADAR1 Capital Management LLC bought a new position in PolyPid during the 4th quarter valued at approximately $451,000. Hedge funds and other institutional investors own 26.47% of the company’s stock.
Analysts Set New Price Targets
A number of brokerages recently issued reports on PYPD. HC Wainwright reiterated a “buy” rating and issued a $13.00 price target on shares of PolyPid in a research note on Tuesday, July 21st. Craig Hallum set a $12.00 target price on shares of PolyPid in a report on Wednesday, July 22nd. Finally, Weiss Ratings upgraded shares of PolyPid from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 23rd. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $11.33.
PolyPid Stock Up 0.2%
Shares of NASDAQ:PYPD opened at $5.11 on Thursday. The firm’s 50 day moving average price is $4.80 and its 200-day moving average price is $4.59. PolyPid Ltd. has a twelve month low of $3.06 and a twelve month high of $5.73. The stock has a market capitalization of $97.50 million, a PE ratio of -3.45 and a beta of 1.41.
PolyPid (NASDAQ:PYPD – Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.03. Analysts expect that PolyPid Ltd. will post -0.92 earnings per share for the current fiscal year.
About PolyPid
PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.
Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.
See Also
- Five stocks we like better than PolyPid
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Want to see what other hedge funds are holding PYPD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PolyPid Ltd. (NASDAQ:PYPD – Free Report).
Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.
